Quest Diagnostics (DGX) Cost of Revenue (2009 - 2026)

Quest Diagnostics has disclosed Cost of Revenue across 18 years of filings, most recently posting $2.0 billion for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $2.0 billion, up 9.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.5 billion (up 10.44% YoY), and the FY2025 annual result was $7.4 billion, up 11.19% from the prior year.
• Cost of Revenue came in at $2.0 billion for Q1 2026 at Quest Diagnostics, up from $1.9 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $2.0 billion in Q1 2026 to a low of $1.5 billion in Q3 2023.
• The 5-year median for Cost of Revenue is $1.6 billion (2022), against an average of $1.7 billion.
• Across the five-year window, Cost of Revenue fell 8.32% in 2022 and increased 14.12% in 2025, its largest moves.
• Quest Diagnostics' Cost of Revenue stood at $1.6 billion in 2022, then slipped by 1.46% to $1.6 billion in 2023, then rose by 13.6% to $1.8 billion in 2024, then rose by 7.54% to $1.9 billion in 2025, then climbed by 3.01% to $2.0 billion in 2026.
• The last three Cost of Revenue figures came in at $2.0 billion (Q1 2026), $1.9 billion (Q4 2025), and $1.9 billion (Q3 2025), per Business Quant data.